2020-07 | Genome-wide association study in a Korean population identifies six novel susceptibility loci for rheumatoid arthritis | 최찬범 |
2011-12 | Genome-Wide Association Study of Rheumatoid Arthritis in Koreans | 최찬범 |
2015-08 | Glucocorticoid Use in Patients With Systemic Lupus Erythematosus: Association Between Dose and Health Care Utilization and Costs | 최찬범 |
2015-03 | High-density genotyping of immune loci in Koreans and Europeans identifies eight new rheumatoid arthritis risk loci | 최찬범 |
2013-06 | HYPERTENSION AND ITS INFLUENCE ON CARDIOVASCULAR RISK AND RA OUTCOMES | 최찬범 |
2012-12 | Impact of comorbidities on TNF inhibitor persistence in rheumatoid arthritis patients: an analysis of Korean National Health Insurance claims data | 최찬범 |
2017-07 | Impact of early diagnosis on functional disability in rheumatoid arthritis | 최찬범 |
2017-10 | Impact of interstitial lung disease on mortality of patients with rheumatoid arthritis | 최찬범 |
2013-06 | IMPACTS OF IMMEDIATE CHANGES IN DMARDS ON OUTCOMES IN RHEUMATOID ARTHRITIS WITH MODERATE-TO-SEVERE ACTIVITY | 최찬범 |
2014-08 | Improving Participation in Clinical Trials of Novel Therapies: Going Back to Basics | 최찬범 |
2016-02 | Imputing Variants in HLA-DR Beta Genes Reveals That HLA-DRB1 Is Solely Associated with Rheumatoid Arthritis and Systemic Lupus Erythematosus | 최찬범 |
2014-06 | INCIDENCE AND RISK FACTORS FOR FRACTURES IN PATIENTS WITH RHEUMATOID ARTHRITIS | 최찬범 |
2016-09 | Incidence and risk factors of fractures in patients with rheumatoid arthritis: an Asian prospective cohort study | 최찬범 |
2016-03 | Influence of HLA-DRB1 Susceptibility Alleles on the Clinical Subphenotypes of Systemic Lupus Erythematosus in Koreans | 최찬범 |
2015-03 | An Internet-based technique for the identification of persons with symptoms of inflammatory polyarthritis of less than 12 weeks | 최찬범 |
2013-10 | Is Isoniazid Treatment For LTBI Safe For RA Patients With TNF Inhibitor Therapy? | 최찬범 |
2018-09 | Isoniazid treatment for latent tuberculosis infection is tolerable for rheumatoid arthritis patients receiving tumor necrosis factor inhibitor therapy | 최찬범 |
2014-06 | KOREAN BIOLOGICS REGISTRY OF PATIENTS WITH SYSTEMIC RHEUMATIC DISEASE (KOBIO): A NATIONWIDE REGISTRY TO ASSESS ADVERSE EVENTS ASSOCIATED WITH BIOLOGIC TREATMENT IN KOREA | 최찬범 |
2012-08 | Korean Observational Study Network for Arthritis (KORONA): Establishment of a Prospective Multicenter Cohort for Rheumatoid Arthritis in South Korea | 최찬범 |
2019-05 | Long-term efficacy, safety and immunogenicity in patients with rheumatoid arthritis continuing on an etanercept biosimilar (LBEC0101) or switching from reference etanercept to LBEC0101: an open-label extension of a phase III multicentre, randomised, double-blind, parallel-group study | 최찬범 |
2017-08 | Long-term Outcomes of Autologous Peripheral Blood Stem Cell Transplantation for Refractory Rheumatic Diseases | 최찬범 |
2017-05 | Lupus nephritis is associated with more corticosteroid-associated organ damage but less corticosteroid non-associated organ damage | 최찬범 |
2012-11 | The major determinants of arterial stiffness in Korean patients with rheumatoid arthritis are age and systolic blood pressure, not disease-related factors | 최찬범 |
2016-03 | Mapping health assessment questionnaire disability index (HAQ-DI) score, pain visual analog scale (VAS), and disease activity score in 28 joints (DAS28) onto the EuroQol-5D (EQ-5D) utility score with the KORean Observational study Network for Arthritis (KORONA) registry data | 최찬범 |
2013-06 | MEDICAL COSTS AND THEIR PREDICTORS IN KOREAN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS | 최찬범 |
2013-06 | METHOTREXATE DOSE AND OUTCOMES IN PATIENTS WITH RHEUMATOID ARTHRITIS | 최찬범 |
2013-05 | Mortality factors in idiopathic inflammatory myopathy: focusing on malignancy and interstitial lung disease | 최찬범 |
2015-06 | Osteomyelitis of bilateral femoral heads after childbirth: A case report | 최찬범 |
2018-05 | Outcomes of multitarget therapy using mycophenolate mofetil and tacrolimus for refractory or relapsing lupus nephritis | 최찬범 |
2017-01 | A phase III, multicentre, randomised, double-blind, active-controlled, parallel-group trial comparing safety and efficacy of HD203, with innovator etanercept, in combination with methotrexate, in patients with rheumatoid arthritis: the HERA study | 최찬범 |